natgillin/translations-raw huggingface dataset:
a mutated ptrgene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and 
mutirani ptr gen, pri čemu mutirani ptr gen kodira protein Proteaze III koji ima smanjenu proteaznu aktivnost ili je mutirani nokaut ptr gen; i
the first fusion protein is SEQ ID NO:1 or an amino acid sequence that is at least 95% identical to SEQ ID NO:1; and 
(a) prvi fuzijski protein je SEQ ID NO: 1 ili aminokiselina koja je najmanje 95% identična sa SEQ ID NO:1; 1
The first important property of the filling medium is that it is immiscible with, and is not dissolved by, any cooling lubricant which is used. 
Prvo važno svojstvo punila je to da se ono ne miješa, niti ne otapa u bilo kojem upotrijebljenom rashladnom sredstvu za podmazivanje.
The process of claim 1 wherein the molar ratio between molecular iodine and 3,5-disubstituted phenol substrate 1 [I2/1] is comprised from 1.1 to 1.3, and the molar ratio between iodic acid and 3,5-disubstituted phenol substrate 1 is comprised from 0.4 to 0.8. 
Postupak prema zahtjevu 1 naznačen time da je molarni odnos između molekulskog joda i supstrata 3,5-disupstituiranog fenola 1 [I2/1] od 1.1 do 1.3, a molarni odnos između jodne kiseline i supstrata 3,5-disupstituiranog fenola 1 je od 0.4 do 0.8.
The device according to claim 1, wherein the endothelial lid comprises a groove as a continuum with its inlet orifice allowing arrival of fresh preservation medium directly on corneal endothelium. The device according to claim 1, wherein the endothelial and epithelial chambers each comprise a technical orifice that allows removal of preservation medium samples for microbiological or biochemical analysis purposes, or the injection of any substance, without compromising sterility within the device. 
Uređaj (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što komora za endotel (18) i komora za epitel (19) sadrže tehničke otvore (11c, 7c), koji omogućuju uzimanje uzoraka konzervacijskog medija u svrhu mikrobiološke ili biokemijske analize, ili injiciranje bilo koje tvari, osobito za olakšavanje brojanja stanica, bez narušavanja sterilnosti unutar bioreaktora.
A method of treating HCV infection in a mammal, comprising administering to the mammal an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof, or a composition thereof. 
Farmaceutski prihvatljiva sol ili ester od spoja prema jednom ili više od zahtjeva 1 do 11, ili njegov sastav, naznačen(a) time, da se upotrebljava u postupku liječenja ili prevencije HCV-infekcije kod sisavaca, koji obuhvaća primjenu na sisavcu učinkovite količine farmaceutski prihvatljive soli ili estera, ili sastava, u kombinaciji s dodatnim antivirusnim sredstvom.
In one embodiment, the present invention provides a kit for treating a solid tumor in a human patient, the kit comprising: 
Komplet za primjenu u liječenju solidnog tumora kod humanog pacijenta, komplet koji sadrži:
A stabilized polymorphous B form of rifaximin in solid state comprising one or more polyols and having water content of less than 4.5%. 
Uporaba kako je zatraženo u zahtjevu 1 spoja za dobivanje rifaksimina u krutom stanju u polimorfnom obliku (B koji ima preostali udio vode manji od 4.5 %.
The integrated rotary mixer and disperser head (1) according to any of the claims 1-21, wherein the various parts are made from a metallic material, such as stainless steel, and rigidly connected to each other by welding so as to form an integral one-piece unit. 
Integrirana rotacijska miješalica i glava raspršivača (1) prema bilo kojoj od tvrdnji od 1 do 21 gdje su razni dijelovi izrađeni od metalnog materijala, kao što je nehrđajući čelik, 1 čvrsto su međusobno spojeni zavarivanjem tako da čine cjelovitu jedinicu.
wherein, the merger is configured to: re-align the data pseudo-streams on a basis of a value of a field of the data packet; 
ponovo poravnati navedene pseudo-tokove (9c,9d) paketa na osnovu vrijednosti polja navedenog paketa podataka;
FIGURE 11 is a view similar to Figure 5 of the second container embodiment in a further assembly step, and 
SLIKA 11 pogled na spremnik sličan onome iz slike 5, koja slika prikazuje drugu izvedbu spremnika u daljnjem koraku sklapanja, i
Initially H2O content in the sample was 0.0762%; during 24 hours at 100% humidity it remains unchanged. 
Početni sadržaj HoO u uzorku bio je 0,0762%; nakon držanja 24 sata pri 100%-tnoj vlazi on je ostao nepromijenjen.
The pharmaceutical composition of claim 9 further comprising a therapeutically effective amount of a chemotherapeutic agent. 
Farmaceutski sastav prema zahtjevu 12, naznačen time, da dodatno obuhvaća terapeutski učinkovitu količinu kemoterapeutskog sredstva.
A person skilled in the art would understand that the conditioning and priming step of the drug delivery device will be affected by the medium in which the device is placed. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 1, naznačen time što je najmanje jedan aktivni sastojak histrelin acetat.
means for measuring of the phase-to-phase voltages (130, Va-b, V b-c, Vc-a) of the back E MFs, to obtain a first phase-to-phase voltage (Va-b) corresponding to the difference between voltage of phase winding A and phase winding B, to obtain a second phase-to-phase voltage (V b-c) corresponding to the difference between voltage of phase winding B and phase winding C and to obtain a third phase-to-phase voltage (Vc-a) corresponding to the difference between voltage of phase winding C and phase winding A; 
mjerač međufaznih napona (130, Va-b, Vb-c, Vc-a) povratnih EMF, radi dobivanja prvog međufaznog napona (Va-b), koji odgovara razlici između napona faznog namota A i faznog namota B, radi dobivanja drugog međufaznog napona (Vb-c), koji odgovara razlici između napona faznog namota B i faznog namota C i radi dobivanja trećeg međufaznog napona (Vc-a), koji odgovara razlici između napona faznog namota C i faznog namota A;
A dry dock according to any one of the preceding Claims wherein the arms comprised inflatable buoyancy tanks. A dry dock according to any of the preceding Claims wherein the platform is pivotally mounted between the arms and the platform support means comprises pairs of extendable and contractable links, the links being operable to expand or contract during lifting or lowering to ensure that the platform remains horizontal relative to its axis of pivotal mounting on the arms when the arms are raised or lowered. 
Suhi dok u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je platforma montirana između krakova na takav način da se može zakretati, a sredstva za držanje platforme posjeduju parove spojnih elemenata koji se mogu rastezati i stezati, pri čemu spojni elementi mogu djelovati tako da se rastežu ili se stežu za vrijeme dizanja ili spuštanja, kako bi osiguralo da platforma ostane u horizontalnom položaju u odnosu na os koja osigurava njeno zakretanje na krakovima, kada se krakovi podižu ili se spuštaju.
Use of a compound according to any of claims 1-10, wherein R2-5 are independently selected from the group consisting of hydrogen, halogen, C1-6-alkyl, preferably methyl, C1-6-alkoxy and C1-6-alkoxy-C1-6-alkoxy, preferably 2-methoxy-ethoxy. 
Upotreba spoja, koji je dan bilo kojim patentnim zahtjevima 1-10, naznačena time, da R** su neovisno odabrani iz skupine koja sadrži vodik, halogen, C; 4-alkil, preferirano metil, C;.5-alkoksi i C1.g-alkoksi-C,.g-alkoksi, preferirano 2-metoksi-etoksi.
The process of paragraph 14, wherein said alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, sec-butanol, t-butanol, pentanol, octanol, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni alkohol se bira iz skupine koju čine metanol, etanol, propanol, izopropanol, butanol, sec-butanol, f-butanol, pentanol, oktanol, te smjese 2 ili više njih.
The method according to claim 12, wherein said disease is asthma or chronic obstructive pulmonary disease (COPD). 
Formulacija praška za upotrebu prema patentnom zahtjevu 11, naznačeno time da bolest jest astma ili kronična opstruktivna plućna bolest.
An antibody or an antigen-binding fragment specifically binding to glycoprotein gB of human cytomegalovirus and capable of neutralizing the bioactivity thereof, where 
Protutijelo ili njegov fragment koji se veže na antigen, naznačen/o time, da se specifično veže na glikoprotein gB od humanog citomegalovirusa te koje/koji može neutralizirati njegovo biološko djelovanje, pri čemu
the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers and/or as body shaping products. 
- derivatom (HBC) hialuronske kiseline umrežene s 1,4-butandiol-diglicil-eterom (BDDE) u masenom omjeru između 10:90 i 90:10, a koji su nova punila i/ili produkti za oblikovanje tijela.
The amount of extract was very low, approx 0.1 mg/mg coating. 
Količina ekstrakta je bila vrlo mala, pribl. 0,1 mg/mg prevlaci.
increasing the humidity of the strands if the measurement shows that they have a humidity that is lower than the desired one, or pre-drying the strands, if the measurement shows that they have a humidity that is higher than the desired one, 
povećanje vlažnosti vlakana ako mjerenje pokaže da je vlažnost manja od željene ili prethodno sušenje vlakana, ako mjerenje pokaže da imaju vlažnost veću od željene,
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, and pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of lower alkyl, halogen and CF3; 
Q je izabrani iz grupe koju čini fenil, piridil, tiazolil, tiofenil, pirimidil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabran iz grupe koju čini Cig alkil, halogen i CF3; gdje
wherein the terpene oil content is the additive content of the terpenes in the terpene profile, wherein the terpene profile consists of terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and myrcene of the inflorescence, wherein the cannabinoid and terpene contents are measured by GC-FID and calculated based on dry weight of the inflorescence, and wherein inflorescences comprising a), b), c), and d) are obtainable from seed deposited under NCIMB 42252 and 42253. 
genotip BT/BD; i sadržaj terpenskog ulja veći od 1%, težinski; gdje je sadržaj terpenskog ulja aditivan sadržaj terpena u terpenskom profilu, gdje se terpenski profil sastoji od terpinolena, a-felandrena, B-ocimena, karena, limonena, Y-terpinena, a-pinena, a-terpinena, B-pinena, fenhola, kamfena, a-terpineola, a-humulena, B-kariofilena, linaloola, kariofilen-oksida, te mircena u inflorescencijiama, gdje se sadržaje kanabinoida i terpena mjeri uz pomoć GC-FID, te izračunava na osnovi suhe težine inflorescencije;
Evaporation of the collected column fractions of interest and removal of the solvent at reduced pressure gave a solid which was further purified using column chromatography (silica, hexane: ethyl acetate (1:1)) to give three main components which were partially resolved into Mosher's ester peaks 1 and 2. 
Evaporacija sakupljenih poželjnih kolonskih frakcija i uklanjanje otapala uz smanjeni tlak daje krutinu koja se dalje pročisti kromatografijom na koloni (silicij, heksan: etil acetat (1:1)) da bi se dobila tri glavna sastojka koja su djelomično riješena u peak-u 1 i peak-u 2 Mosher-ovog estera.
placing in each case a discharge line (20) transversely across the second side of the series of core elements (4) and across the material web parts (6) which extend across the series, 
- < usvakom slučaju postavljanje ispusne linije (20) transverzalno duž druge strane serije jezgrenih elemenata (4) i duž dijelova mreže materijala (6) koji se pružaju preko serije,
k represents 0 or 1. The compound according to claim 4 or a pharmacologically acceptable salt thereof, wherein R8a represents a C1-C4 alkyl group, and 
Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje R* predstavlja C,-C, alkil skupinu, i k predstavlja 0.
Intermediate 30 was prepared (52% yield) according to the procedure for intermediate 25. 
o Intermedijer 30 je pripremljen (52% prinos) prema postupku za Intermedijer 25.
compressing the at least two rows (13) of rolls (1, 2) being arranged next to each other; and 
(b) stlačivanjem najmanje dva reda (13) valjaka ili paketa (22) ploča koji su postavljeni jedan do drugog; i
The invention discloses an expression vector capable of expressing a polypeptide. 
Vektor ekspresije sposoban izraziti nukleinsku kiselinu sukladno Tvrdnjama 4 ili 5.
and/or, in step (2), the organic base is selected from the group consisting of ammonia aqueous, morpholine, pyridine, triethyl amine, ethanol amine, ethylene diamine, 4-dimethylaminopyridine, diisopropyl ethyl amine and any combination thereof; 
i / ili, u koraku (2), organska baza je odabrana iz skupine koja sadrži vodeni amonijak, morfolin, piridin, trietil amin, etanol amin, etilen diamin, 4-dimetilaminopiridin, diizopropil etil amin i bilo koje kombinacije istih;
A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 11 in the treatment of breast cancer, ovarian cancer, prostate cancer, colorectal cancer, mesothelioma and other sarcomas, neuroblastoma, lymphoma, leukaemia and melanoma. 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 11 u liječenju karcinoma dojke, karcinoma jajnika, karcinoma prostate, kolorektalnog karcinoma, mezotelioma i drugih sarkoma, neuroblastoma, limfoma, leukemije i melanoma.
Formulation and Administration 
D. Formulacija i aplikacija
A process according to any one of the claims 1 to 3, characterised in that said open-cell foam comprises a reticulated foam, in particular a reticulated polyurethane foam. 
Postupak prema jednom od zahtjeva 1 do 4, naznačen time da stanično otvorena pjenasta tvar obuhvaća jednu retikuliranu pjenastu tvar.
Fig. 9 is a sectional plan view of two elements according to another embodiment of the invention. 
je nacrt presjeka dvaju elemenata prema nekom drugom uobličenju predmetnog izuma.
and R2, together with the nitrogen atom to which they are attached, form a pyrrolidine, piperidine, or morpholine ring; 
i R2, zajedno s atomom dušika na kojega su priključeni, tvore pirolidin-prsten, piperidin-prsten ili morfolin-prsten;
is selected from hydrogen and halo; 
R3 je odabran od vodika i halo;
The medicament delivery device of claim 2, wherein the third mechanically coded interface device is arranged on a second interface member having a ring configuration, and the second interface member is releasably attached to the proximal end of the distal housing part, such that the third mechanically coded interface device protrudes through a transversal slot on the proximal end of the distal housing part. 
Uređaj za isporuku lijeka prema zahtjevu 11, naznačen time da treća mehanički kodirana sredstva sučelja (111) smještena na drugom elementu sučelja (170A, 170B) imaju konfiguraciju oblika prstena i pri čemu je drugi element sučelja rastavljivo spojen na proksimalni kraj distalnog kućišta, tako da treća mehanički kodirana sredstva sučelja (111) proviruju kroz poprečni utor (114) na proksimalnom kraju distalnog kućišta.
elimination of product segregation when e.g. ingredients with divergent particle size distributions are used; 
Te su prednosti npr.: - < izbjegavanje segregacije proizvoda kada se npr. koriste sastojci s različitim rasponom veličine čestica;
The method of claim 14, wherein the Crenolanib or a salt thereof is provided as a single agent in treatment of patients with the proliferative disease that is either refractory to, or has relapsed after prior treatment with a chemotherapeutic agent. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens u liječenju subjekata s akutnom mijeloičnom leukemijom (AML) koja je ili refraktorna ili je relapsirala nakon prethodnog liječenja kemoterapijskim agensom.
A process according to claim 2 wherein the lignocellulosic biomass has a distribution of particle sizes in which at least 20% (w/w) are between 26-70 mm in size before pre-treatment. 
Postupak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što najmanje 20% (tež./tež.) lignocelulozne biomase ima veličinu vlakana preko 26 mm.
The method according to claim 1 wherein alignment of said nano-fibrils is improved by the use of a hyperbolic die designed to match the rheological properties of the suspension. 
Postupak prema bilo kojem zahtjevu od 1 do 13 naznačen time da se poravnavanje nano-vlakana poboljšava korištenjem hiperboličkog kalupa konstruiranog da odgovara reološkim svojstvima suspenzije.
The method of claim 4, wherein the GPR119 agonist is a selective GPR119 agonist. 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist je selektivni GPRI19 agonist.
An inserter according to any of the previous claims, characterised in that it further comprises locking means for reversibly locking the intrauterine system in relation to the plunger via a removal string of the intrauterine system, said locking means being controllable by the slider and/or the insertion tube 
Aplikator za umetanje prema bilo kojem od prethodnih zahtjeva, naznačen time što dalje obuhvaća sredstva za zaključavanje za reverzibilno zaključavanje intrauterinog sustava u odnosu na klip putem trake za uklanjanje intrauterinog sustava, ta sredstva za zaključavanje se mogu kontrolirati klizačem i/ili cjevčicom za umetanje.
the MCs are peripheral blood mononuclear cells (PBMCs); and/or 
(a) mononuklearne stanice su mononuklearne stanice periferne krvi (PBMC); i/ili
Suitably X1 is oxygen. 
Najprikladnije je X! kisik.
An isolated nucleic acid encoding the polypeptide of any one of claims 1-10. 
Izolirana nukleinska kiselina koja kodira polipeptid iz bilo kojeg od patentnih zahtjeva 1-10.
with a compound of formula (III): wherein LG1 represents a leaving group. 
(ll) sa spojem sa formulom (III): pri čemu LG, predstavlja izlaznu skupinu.
wherein the processing fluid is boron-free by containing less than 0.5 wt% boron and free of a secondary amine by containing less than 0.5 wt% secondary amine. 
pri čemu tekućina za obradu je bez bora uz udio manje od 0.5 mas.% bora i bez sekundarnog amina uz udio manje od 0.5 mas.% sekundarnog amina.
The method of claim 17, wherein said antibodies or antibody fragments selected in step (c) inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Postupak prema zahtjevu 17, gdje to protutijelo ili fragmenti protutijela izabranog u koraku (c) inhibira vezanje HLA-c alel molekule koja ima Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
The ventilation valve according to claim 15, wherein the panel hinges about a hinge axis, which extends parallel to a single pair of the opposite rectangle sides. 
Ventilacijski ventil prema zahtjevu 12, naznačen time što se šarka ploče nalazi oko zglobne osi, koja se proteže paralelno s jednim parom suprotnih pravokutnih strana.
inserting a second dialysis liquid in the two further chambers for the second dialysis liquid; and applying an electric field over the membrane stack; 
Il. umetanje druge tekućine za dijalizu u dvije daljnje komore za drugu tekućinu za dijalizu; i II. primjenu električnog polja na stog membrana;
A compound according to claim 2 that is (4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone citrate salt. 
Spoj u skladu sa zahtjevom 2, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon citratna sol.
An LC-PDA analysis was performed to identify the substances that are mainly responsible for the UV absorption characteristics of the light stabilising composition described in example 1. 
LC-PDA analiza se provede radi identifikacije tvari koje su najviše odgovorne za karakteristike UV apsorpcije pripravka za stabiliziranje na svjetlo opisanog u primjeru 1.
The process of any one of claims 2 to 7, wherein said first solvent is selected from the group consisting of CH2Cl2, chlorobenzene, t-butylmethylether, and toluene. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeno prvo otapalo se bira iz skupine koju čine CH2Cl2, klorbenzen, t-butilmetil-eter i toluen.
conversion of E*, particularly under conditions of a Wittig reaction, to create compound 4* (having a second benzyl protection group at the nitrogen atom instead of the phenyl fluorenyl group in compound 4); 
B E (c) prevođenje spoja E ili spoja E*, naročito u uvjetima Wittigove reakcije, kako bi se dobio spoj 4 ili spoj 4*; s 2
The compound or the pharmaceutical composition for use according to claim 14 or 15, wherein the central nervous system disorder is selected from the group of schizophrenia (in particular, negative symptoms or residual symptoms thereof), generalized anxiety disorder, bipolar disorder (I or II), migraine, behavioral and psychological symptoms of dementia, epilepsy or convulsive disorders, panic disorder, mixed anxiety and depression, and agoraphobia. 
Spoj ili farmaceutski pripravak za upotrebu prema zahtjevu 14 ili 15, naznačen time da je poremećaj središnjeg živčanog sustava odabran iz skupine koju čine shizofrenija (naročito njezini negativni simptomi ili rezidualni simptomi), opći anksiozni poremećaj, bipolarni poremećaj (I ili II), migrena, bihevioralni 1 psihički simptomi demencije, epilepsija ili konvulzivni poremećaji, panični poremećaj, miješana anksioznost i depresija, te agorafobija.
a second polynucleotide encoding for a protein of interest, whereby said derivative is a polypeptide molecule which is at least 70% identical in sequence with the original CERT sequence or its complementary sequence or said derivative is a homologous CERT sequence from a different organism and whereby said mutant is based on targeted modification of CERT sequences by substitution, insertion or deletion of one to ten amino acids. 
drugi protein kodira za korisni protein, pri čemu spomenuti derivat je polipeptidna molekula koja je barem 70 % istovjetna u sekvenci s originalnom CERT-sekvencom ili njenom komplementarnom sekvencom ili je spomenuti derivat homologna CERT-sekvenca iz različitog organizma, te pri čemu je spomenuti mutant baziran na ciljanoj modifikaciji CERT-sekvenci pomoću zamjene, umetanja ili izbacivanja od jedne do deset amino kiselina.
In the most of preservatives the solution molar ratios Cu:amine are lower than 1:12. 
U većini konzervansa, molarni omjeri otopine su niži od 1:12.
wherein the percentages of the ingredients are selected from the ranges quoted to total 100%; and 
nanošenja omotača od kompozicije vodenog omotača na supstrat;
at least one protrusion having at least one coupling portion having enlarged section; and 
najmanje jedno izbočenje (9), koje ima najmanje jedan spojni dio (9a) s povećanim dijelom;
G is CH or N; R′ is selected from the following groups: H, CH3, 
R, je odabran od sljedećih: H, CH,, ili odgovarajuće farmaceutski prihvatljive soli.
The ingredients in the capsule preferably constitute the “bottleneck” of the flow path of the water and will therefore cause a pressure drop between the upstream and the downstream side of the liquid flow through the capsule, which pressure drop can even increase during the interaction between the liquid and the ingredients for example due to a swelling of the ingredients. 
Poželjno je da sastojci u čahuri čine "usko grlo" za put kojim protječe voda i prema tome će se uzrokovati pad tlaka između uzvodne i nizvodne strane protoka tekućine kroz čahuru, koji pad tlaka se može čak i povećati za vrijeme miješanja između tekućine i sastojaka, na primjer, zbog bubrenja sastojaka.